- $11.45bn
- $9.33bn
- $4.24bn
- 92
- 23
- 50
- 55
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 9.61 | ||
| PEG Ratio (f) | 0.14 | ||
| EPS Growth (f) | 197.99% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.32 | ||
| Price to Tang. Book | 3.6 | ||
| Price to Free Cashflow | 45.97 | ||
| Price to Sales | 2.7 | ||
| EV to EBITDA | 61.94 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 1.61% | ||
| Return on Equity | 0.76% | ||
| Operating Margin | 1.45% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 2,666.7 | 2,986.27 | 3,394.64 | 3,695.65 | 4,241.22 | 4,668.84 | 5,097.73 | 14.46% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | -64.3 | +73.8 | -88.7 | +1780.7 | +17.35 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company operates in two therapeutic areas. One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of six products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), NIKTIMVO (axatilimab-csfr), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The Company's pipeline also includes two first-in-class small molecule antagonist of Mas-related G protein-coupled receptor (MRGPRX2) and INCB000547, an oral MRGPRX4 antagonist.
Directors
- Herve Hoppenot CHM (61)
- Christiana Stamoulis CFO (51)
- Dashyant Dhanak EVP (60)
- Maria Pasquale EVP (55)
- Jonathan Dickinson EVP (53)
- Paula Swain EVP (63)
- Barry Flannelly EVP (63)
- Vijay Iyengar EVP (48)
- Michael Morrissey EVP (57)
- Steven Stein EVP (54)
- Julian Baker LED (54)
- Otis Brawley DRC (62)
- Jean-Jacques Bienaime IND (67)
- Paul Clancy IND (59)
- Wendy Dixon IND (65)
- Jacqualyn Fouse IND (59)
- Edmund Harrigan IND (68)
- Katherine High IND (69)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- April 8th, 1991
- Public Since
- December 6th, 1993
- No. of Shareholders
- 107
- No. of Employees
- 2,617
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 193,524,350
- Address
- 1801 Augustine Cut-Off, WILMINGTON, 19803
- Web
- https://www.incyte.com/
- Phone
- +1 3024986700
- Contact
- Ben Strain
- Auditors
- Ernst & Young LLP
Upcoming Events for INCY
Q1 2025 Incyte Corp Earnings Call
Incyte Corp Annual Shareholders Meeting
Q2 2025 Incyte Corp Earnings Release
Q3 2025 Incyte Corp Earnings Release
Similar to INCY
Alnylam Pharmaceuticals
NASDAQ Global Select Market
Amgen
NASDAQ Global Select Market
Amneal Pharmaceuticals
NASDAQ Global Select Market
Amphastar Pharmaceuticals
NASDAQ Global Select Market
Apellis Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the Incyte share price?
As of Today at 21:16 UTC, shares in Incyte are trading at $59.16. This share price information is delayed by 15 minutes.
How has the Incyte share price performed this year?
Shares in Incyte last closed at $59.16 and the price had moved by +15.59% over the past 365 days. In terms of relative price strength the Incyte share price has outperformed the S&P500 Index by +6.7% over the past year.
What are the analyst and broker recommendations for Incyte?
The overall consensus recommendation for Incyte is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Incyte dividend yield?
Incyte does not currently pay a dividend.
Does Incyte pay a dividend?
Incyte does not currently pay a dividend.
When does Incyte next pay dividends?
Incyte does not currently pay a dividend.
How do I buy Incyte shares?
To buy shares in Incyte you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Incyte?
As of the previous close price of $59.16, shares in Incyte had a market capitalisation of $11.45bn.
Where are Incyte shares listed?
Here are the trading details for Incyte:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: INCY
What kind of share is Incyte?
Based on an overall assessment of its quality, value and momentum Incyte is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Incyte share price forecast for 2025?
The analyst consensus target price for shares in Incyte is $73.96. That is 25.02% above the last closing price of $59.16.
Analysts covering Incyte currently have a consensus Earnings Per Share (EPS) forecast of $5.83 for the next financial year.
Find out moreWhat is the trend in the Incyte share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Incyte. Over the past six months, its share price has underperformed the S&P500 Index by -4.17%.
As of the last closing price of $59.16, shares in Incyte were trading -12.55% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Incyte PE Ratio?
The Incyte PE ratio based on its reported earnings over the past 12 months is 9.61. The shares last closed at $59.16.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Incyte?
Incyte's management team is headed by:
- Herve Hoppenot - CHM
- Christiana Stamoulis - CFO
- Dashyant Dhanak - EVP
- Maria Pasquale - EVP
- Jonathan Dickinson - EVP
- Paula Swain - EVP
- Barry Flannelly - EVP
- Vijay Iyengar - EVP
- Michael Morrissey - EVP
- Steven Stein - EVP
- Julian Baker - LED
- Otis Brawley - DRC
- Jean-Jacques Bienaime - IND
- Paul Clancy - IND
- Wendy Dixon - IND
- Jacqualyn Fouse - IND
- Edmund Harrigan - IND
- Katherine High - IND